Sexual function in patients with schizophrenia on anti-psychotics: a comparative study of hyperprolactinemia-inducing and hyperprolactinemia non-inducing antipsychotics
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20262854Keywords:
Antipsychotics, Arizona sexual experience scale, Hyperprolactinemia, Schizophrenia, Sexual dysfunctionAbstract
Background: Sexual dysfunction is a common but often under-recognized adverse effect in patients with schizophrenia receiving antipsychotic therapy. Hyperprolactinemia induced by certain antipsychotics has been implicated as a major contributing factor. This study aimed to compare sexual function among patients receiving hyperprolactinemia-inducing and hyperprolactinemia non-inducing antipsychotics and to assess whether sexual dysfunction is related to antipsychotic-induced hyperprolactinemia or the underlying illness itself.
Methods: A prospective observational study was conducted in the Department of Psychiatry at Sri Ramachandra Hospital, Chennai, from March to July 2025. Sixty patients diagnosed with schizophrenia according to ICD-10 criteria and receiving antipsychotic therapy were enrolled. Patients were categorized into two groups: hyperprolactinemia-inducing antipsychotics (olanzapine, haloperidol, risperidone) and hyperprolactinemia non-inducing antipsychotics (aripiprazole, cariprazine, lurasidone). Sexual function was assessed using the Arizona Sexual Experience Scale (ASEX), and serum prolactin levels were measured. Statistical analyses included independent t-tests and one-way ANOVA, with p<0.05 considered significant.
Results: Of the 60 participants, 32 (53.3%) were males and 28 (46.7%) were females. Patients receiving hyperprolactinemia-inducing antipsychotics demonstrated significantly higher ASEX scores compared with those receiving hyperprolactinemia non-inducing agents (21.53±2.97 vs 15.70±2.93; p=0.0005). Serum prolactin levels were also significantly elevated in the hyperprolactinemia-inducing group (137.5±51.60 ng/mL vs 33.2±17.14 ng/mL; p=0.0005). Within-group analysis revealed that haloperidol was associated with the highest ASEX scores and prolactin levels among prolactin-raising agents, while aripiprazole exhibited the lowest values among prolactin-sparing drugs.
Conclusions: Sexual dysfunction was significantly more prevalent among patients receiving hyperprolactinemia-inducing antipsychotics and was strongly associated with elevated serum prolactin levels. However, the presence of sexual dysfunction in some patients receiving prolactin-sparing agents suggests that factors related to schizophrenia itself may also contribute. Careful selection of antipsychotic therapy and routine monitoring of sexual function and prolactin levels may improve treatment adherence and quality of life in patients with schizophrenia.
References
World Health Organization. Schizophrenia, 2022. Available at: https://www.who.int/news-room/fact-sheets/detail/schizophrenia. Accessed 01 January 2026.
Montejo AL, Majadas S, Rico-Villademoros F, Llorca G, De La Gandara J, Franco M, et al. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sex Med. 2010;7(10):3404-13.
Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol. 2011;26(3):130-40.
Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421-53.
Holt RIG, Peveler RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf). 2011;74(2):141-7.
Peveler RC, Branford D, Citrome L, Fitzgerald P, Harvey PW, Holt RIG, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol. 2008;22(2 Suppl):98-103.
Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psych. 2011;45(10):830-7.
Milano W, D'Acunto CW, De Rosa M, Festa M, Milano L, Petrella C, et al. Recent clinical aspects of hyperprolactinemia induced by antipsychotics. Rev Recent Clin Trials. 2011;6(1):52-63.
Korchia T, Achour V, Faugere M, Albeash A, Yon DK, Boyer L, et al. Sexual Dysfunction in Schizophrenia: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2023;80(11):1110-1120.
Kirino E. Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics. Ann Gen Psych. 2017;16(1):43.
Yoshida K, Takeuchi H. Sexual dysfunction in schizophrenia: a review. Neuropsychiatr Dis Treat. 2019;15:27612771.
Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C. Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance. Encephale. 2014;40(1):86-94.
Kirino E. Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics. Hum Psychopharmacol. 2017;32(5):e2629.
Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-2314.
Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacoth. 2009;29(1):64-73.
Park YW, Kim Y, Lee JH. Antipsychotic-induced sexual dysfunction and its management. World J Mens Health. 2012;30(3):153-9.
Riecher-Rössler A, Rybakowski JK, Pflueger MO, et al. Hyperprolactinemia in antipsychotic-treated patients and its clinical consequences. Management of antipsychotic-induced hyperprolactinemia. BJPsych Adv. 2018;24(5):295-304.
Downloads
Published
How to Cite
Issue
Section
